Mazor Robotics’ (MZOR) Hold Rating Reiterated at Barclays PLC
Mazor Robotics Ltd. (NASDAQ:MZOR)‘s stock had its “hold” rating reiterated by equities research analysts at Barclays PLC in a note issued to investors on Wednesday. They presently have a $34.00 target price on the medical instruments supplier’s stock. Barclays PLC’s price objective would indicate a potential downside of 35.84% from the company’s current price.
Several other equities research analysts also recently weighed in on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Mazor Robotics in a research report on Wednesday, August 30th. Ladenburg Thalmann Financial Services set a $54.00 price target on Mazor Robotics and gave the stock a “buy” rating in a research report on Wednesday, August 30th. Finally, Zacks Investment Research raised Mazor Robotics from a “sell” rating to a “buy” rating and set a $41.00 price target on the stock in a research report on Tuesday, August 15th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $37.67.
Shares of Mazor Robotics (NASDAQ MZOR) traded down 1.85% during mid-day trading on Wednesday, hitting $52.99. The company had a trading volume of 448,330 shares. The company has a 50-day moving average price of $46.56 and a 200-day moving average price of $39.03. The company’s market capitalization is $1.28 billion. Mazor Robotics has a 1-year low of $20.19 and a 1-year high of $55.66.
Mazor Robotics (NASDAQ:MZOR) last announced its quarterly earnings results on Tuesday, August 1st. The medical instruments supplier reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.09. The company had revenue of $15.46 million for the quarter, compared to the consensus estimate of $15.38 million. Mazor Robotics had a negative return on equity of 28.51% and a negative net margin of 37.66%. The firm’s revenue for the quarter was up 86.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.09) EPS. On average, equities analysts anticipate that Mazor Robotics will post ($0.77) EPS for the current year.
Large investors have recently bought and sold shares of the company. Credit Suisse AG grew its position in shares of Mazor Robotics by 66.5% during the 1st quarter. Credit Suisse AG now owns 330,000 shares of the medical instruments supplier’s stock valued at $9,824,000 after acquiring an additional 131,804 shares during the period. Oracle Investment Management Inc. grew its position in shares of Mazor Robotics by 13.0% during the 4th quarter. Oracle Investment Management Inc. now owns 2,816,635 shares of the medical instruments supplier’s stock valued at $28,617,000 after acquiring an additional 323,724 shares during the period. Private Advisor Group LLC acquired a new stake in shares of Mazor Robotics during the 2nd quarter valued at about $517,000. Biondo Investment Advisors LLC acquired a new stake in shares of Mazor Robotics during the 2nd quarter valued at about $675,000. Finally, Suffolk Capital Management LLC acquired a new stake in shares of Mazor Robotics during the 3rd quarter valued at about $1,654,000. Hedge funds and other institutional investors own 25.92% of the company’s stock.
Mazor Robotics Company Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.